This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
2/11/2026
Operator
Conference Operator
Good day and welcome to the HANSA Biopharma fourth quarter and full year 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star then two. We ask that you limit yourself to one question, please. Please note that this event is being recorded. I would now like to turn the conference over to Hansa Biopharma CEO, Renee Aguiar-Lucander. Please go ahead.
Renée Aguiar-Lucander
Chief Executive Officer
Thank you. Good afternoon and good morning. Welcome to the Hansa Biopharma Conference Calls Review Q4 and the results for the full year of 2025. I'm Renee Aguiar-Lucander. CEO of Hansa Biopharma, and joining me today is Evan Ballantyne, Chief Financial Officer, Richard Phillipson, Chief Medical Officer, and Maria Thornson, Chief Operating Officer and President, U.S.
Maria Thornson
Chief Operating Officer and President, U.S.
Please turn to slide two.
You're reading a preview of the HNSA.ST Q4 2025 earnings call.
Free account.
Disclaimer